Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.83 +0.06 (+0.23%)
Official Closing Price Updated: 4:10 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Plan Ahead! 7 Stocks to Buy Before Any Market Downturn Occurs
While red ink in the broader equities space could hurt most entities, these stocks to buy for a market downturn might be resilient. 
Via InvestorPlace
3 Volatility-Busting, Low-Beta Stocks to Grab Now
These are the undervalued low-beta stocks to buy as they represent blue-chip names with robust cash flow outlook. 
Via InvestorPlace
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Investors are so worried about a one-off situation that they're looking right past the bigger bullish picture. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Hot on the Hedge Funds’ Trail: 3 Stocks Worth Your Bet?
With a 7.1% Q4 leap, hedge fund stocks underscore their role as incredible bets in a well-rounded portfolio. 
Via InvestorPlace
BNTX DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Analyst Scoreboard: 9 Ratings For Pfizer
Via Benzinga
This Is What Whales Are Betting On Pfizer
Via Benzinga
BNTX DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
3 Overhyped Stocks Every Smart Investor Should Ignore
Learn why smart investors avoid overhyped stocks, highlighting three companies facing significant challenges in today's volatile market. 
Via InvestorPlace
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
From Pfizer Inc.
Via Business Wire
Pfizer's Respiratory Syncytial Virus Vaccine Maintains Staying Power In Older Adults Through 2nd RSV season, Study Finds
Pfizer reports strong 77.8% efficacy for Abrysvo vaccine against RSV in adults 60+. Durable 88.9% efficacy after two seasons. Consistent protection for RSV A and B. No new adverse events. FY2023 sales... 
Via Benzinga
BNTX IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - February 29, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
From Pfizer Inc.
Via Business Wire
3 Starter Long-Term Stocks Every New Investor Should Own
These three long-term stocks for new investors provide a solid foundation, harmonizing risk with rewarding prospects for the long haul. 
Via InvestorPlace
3 Forgotten Dividend Stocks With a Yield of Over 5%
These are the undervalued dividend stocks to buy as they represent fundamentally strong companies poised for accelerated growth. 
Via InvestorPlace
7 Dividend Stocks to Buy to Secure Steady Income
Unlock financial growth with 7 standout dividend stocks in real estate, industrial, pharma, and telecom sectors for long-term success. 
Via InvestorPlace
3 Overextended Stocks That Need to Slash Their Dividends ASAP
The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big. 
Via InvestorPlace
Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst
Income investors can enjoy the nearly 6% dividend yield even if growth doesn't return. 
Via The Motley Fool
Global Health and Education Projects and Kano Independent Research Centre Trust Sign Strategic Partnership to Support Researchers in Africa
Via AB Newswire
7 Defensive Stocks to Weather Any Downturn With Ease
While circumstances may look favorable in the market, it doesn’t hurt for investors to consider defensive stocks – just in case. 
Via InvestorPlace
3 Blue-Chip Stocks to Buy to Bolster Your Portfolio
Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare. 
Via InvestorPlace
3 Steal-of-a-Deal Stocks to Snap Up Right Now
Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now. 
Via InvestorPlace
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
7 Struggling Stocks to Sell Before Q2 2024
When you have stocks to sell, you also have an opportunity to reallocate that money into investments with a better growth window. 
Via InvestorPlace
Getting a Tax Refund? This Warren Buffett Stock Is a Great Way to Put It to Work
This Warren Buffett stock is a safe and proven capital appreciation vehicle. 
Via The Motley Fool
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.